What Is The Leading Driver Behind Impact Of Rising Chronic Eye Conditions On Vision Loss And Treatment Demand Market Expansion in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Glaucoma Industry Market Size Be by 2025?
The overall valuation of the glaucoma market has shown robust expansion across the most recent years, projected to ascend from $7.76 billion in 2024 to reach $8.2 billion by 2025, reflecting a consistent compound annual growth rate (CAGR) of 5.6%; this upward trajectory during the past period is fundamentally linked to several factors, including elevated public consciousness regarding ocular well-being, amplified expenditures on healare services, the wider integration of virtual platforms for ophthalmological consultations, continuous development of medical facilities, and a rise in state-sponsored health programs.

What's the Long-Term Growth Forecast for the Glaucoma Market Size Through 2029?
Anticipation surrounds the glaucoma sector, projecting robust expansion over the ensuing years, with the market value poised to reach $10.12 billion by 2029, driven by a compound annual growth rate (CAGR) of 5.4%; this foroming upswing is fundamentally linked to several key causative factors, such as the demographic shift toward an older populace, the increasing incidence of glaucoma diagnoses, mounting interest in less invasive surgical procedures, the growing prevalence rates of both diabetes and hypertension, while paramount trends shaping this trajectory encompass progress in diagnostic instrumentation, the introduction of novel pharmaceutical interventions, ongoing technological leaps in surgical apparatus, wider deployment of combination therapeutic approaches, and the increasing integration of robotic techniques into surgical practice.

View the full report here:
https://www.thebusinessresearchcompany.com/report/glaucoma-global-market-report

What Are the Key Growth Drivers Fueling the Glaucoma Market Expansion?
The increasing incidence of long-term visual ailments is forecast to boost the expansion of the glaucoma market in the future. These persistent eye disorders, which frequently result in ongoing visual difficulty or distress necessitating continuous care or intervention, are becoming more common attributable to demographic shifts toward older age, heightened digital device usage, various lifestyle elements, and a greater occurrence of illnesses such as diabetes and high blood pressure. Therapeutic interventions for glaucoma are essential in managing these chronic conditions by reducing internal eye pressure, halting additional harm to the optic nerve, and maintaining sight, given that unmanaged glaucoma can cause permanent vision loss. As an illustration, the United Kingdom's National Health Service reported in December 2024 that in 2024, more than two million residents in the UK currently experience sight loss, with that figure anticipated to climb by 27%, nearing 2.8 million, by 2035; consequently, this upward trend in chronic eye health issues is serving as a primary impetus for the glaucoma market's growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20820&type=smp

What Are the Key Trends Driving Glaucoma Market Growth?
Leading enterprises within the glaucoma sector are concentrating efforts on engineering novel treatments, particularly Rho-kinase (ROCK) inhibitors, designed to provide a twofold therapeutic effect: lowering intraocular pressure by both facilitating the discharge of aqueous humor and promoting the relaxation of trabecular meshwork cells, thereby establishing their efficacy in glaucoma management.These ROCK inhibitors function by selectively inhibiting the activity of Rho-kinase enzymes, which play a crucial role in governing cellular contraction, thereby serving to alleviate intraocular pressure associated with glaucoma.As an illustration, in July of 2023, Santen Pharmaceutical Co. Ltd., a firm specializing in ocular care products and headquartered in Japan, introduced Roclanda to the United Kingdom market.Roclanda constitutes a novel fixed-dose combination therapy juxtaposing latanoprost with netarsudil, a new Rho-kinase (ROCK) inhibitor, whose mechanism effectively decreases intraocular pressure (IOP) by addressing issues within the trabecular meshwork; its approved use covers adult individuals suffering from primary open-angle glaucoma or ocular hypertension who have found that using a prostaglandin or netarsudil as a singular therapy was insufficient for IOP control.The arrival of Roclanda across Europe signifies a significant milestone, representing the initial introduction of an entirely new category of glaucoma pharmaceutical in a quarter-century, signaling a major advancement in care options.The combination of netarsudil and latanoprost within Roclanda creates a synergistic effect that enhances fluid outflow via both the trabecular (conventional) route and the uveoscleral (unconventional) pathways, ensuring a thorough strategy for controlling elevated IOP.

How Is the Glaucoma Market Segmented?
The glaucomamarket covered in this report is segmented -

1) By Disease Type: Open Angle Glaucoma; Angle Closure Glaucoma; Other Disease Types
2) By Diagnosis: Tonometry; Ophthalmoscopy; Perimetry; Gonioscopy
3) By Drug Class: Beta Blockers; Prostaglandins; Alpha Adrenergic Agonist; Carbonic Anhydrase Inhibitors; Combination Drugs; Other Drug Classes
4) By Administration: Oral; Injections; Intravitreal; Other Administrations
5) By End-User: Hospitals; Ophthalmic Clinics; Ambulatory Surgical Centers

Subsegments:
1) By Open Angle Glaucoma: Primary Open Angle Glaucoma (POAG); Secondary Open Angle Glaucoma
2) By Angle Closure Glaucoma: Primary Angle Closure Glaucoma; Secondary Angle Closure Glaucoma
3) By Other Disease Types: Normal-Tension Glaucoma; Pigmentary Glaucoma; Pseudoexfoliative Glaucoma; Congenital Glaucoma

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=20820&type=smp

Which Companies Are Leading the Charge in Glaucoma Market Innovation?
Major companies operating in the glaucoma market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Limited, Bausch & Lomb Corp., Carl Zeiss Meditec, Santen Pharmaceuticals Co. Ltd., Topcon Corporation, Thea Laboratoires, Corza Ophthalmology, Lumenis Ltd., Alcon Inc., Viva BioInnovator, Glaukos Corporation, Iridex Corporation, Nova Eye Medical Ltd., Renova Life Sciences Private Limited, Qlaris Bio Inc., PolyActiva Pty Ltd., Nidek Co. Ltd., Haag-Streit AG

Which Regions Are Leading the Global Glaucoma Market in Revenue?
North America was the largest region in the glaucoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glaucoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20820

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.